ANI Pharmaceuticals Announces Offer to Acquire Egetis

ANI Pharmaceuticals has announced a recommended public offer to acquire Egetis Therapeutics AB for approximately $560 million. This acquisition aims to expand ANI's rare disease business, leveraging Egetis's lead asset, EMCITATE®, an approved treatment for MCT8 deficiency with an estimated peak sales potential of over $300 million. The deal is unanimously recommended by Egetis's Board and supported by shareholders controlling 42% of its shares.